Coherus BioSciences
333 Twin Dolphin Dr, #600
Redwood City
CA
94065
United States
Tel: 800-794-5434
Website: https://www.coherus.com/
About Coherus BioSciences
Coherus is focused on expanding patient access to important, cost-effective medicines and delivering significant savings to the U.S. healthcare system. Every member of the Coherus team is dedicated, motivated, and passionate about expanding patient access to lifesaving therapeutics. Our colleagues are experts in analytical and process sciences, deeply experienced in clinical development and regulatory affairs, and have proven commercial and marketing capabilities. Everyone at Coherus is committed to meeting the highest standards, inspiring our teammates, and achieving our goals.
Coherus was founded a decade ago to provide the highest quality biosimilar treatments to patients. We are proud to now be expanding our legacy—to build on our success with biosimilars and to focus our core strengths on immuno-oncology.
At Coherus, our employees are our most important asset. We have a dynamic and rewarding organizational culture that offers the opportunity to work with leading industry professionals who are dedicated to making a difference for patients. We are looking for individuals who see unlimited potential in themselves and are motivated by a continuous passion for breaking down barriers and expanding access to lifesaving therapeutics.
Coherus offers a competitive total rewards program comprised of various elements, including competitive base pay, short- and long-term incentives in the form of performance-based cash and equity, as well as health and wellness benefits that include
• Healthcare: Coherus pays 90% of premiums for medical, dental, and vision coverage for our
employees, their eligible spouses, dependents, and domestic partners.
• Health Savings and Flexible Spending Accounts
• Group Life, Disability, and Group Accident Insurance
• 401(k) with company match, and an Employee Stock Purchase Plan (ESPP)
• Paid Time Off (PTO)
• Health & Wellness programs, including a Health Club Reimbursement and an Employee Assistance Program
Health & Wellness programs, including a Health Club Reimbursement and an Employee Assistance Program
In addition to providing attractive rewards packages, we encourage and support our employees to find the right balance of work and personal time. Coherus offers a variety of activities, perks, and holidays that encourage employees to have a healthy outlook, spend time outside of work with friends and family, and foster a productive and collaborative work environment. Our culture is one in which we challenge and support all our team members to do their best work.
For more information about Coherus, please check out: https://www.coherus.com/about-coherus/
255 articles about Coherus BioSciences
-
Keep up with the regulator’s latest rulings on novel drugs and expanded indications, as the second half of 2023 promises some major milestone FDA approvals.
-
Coherus and Junshi Biosciences Announce Publication of Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Trial Evaluating LOQTORZI™ (toripalimab-tpzi) as Treatment for Nasopharyngeal Carcinoma, in the JAMA
11/28/2023
Coherus BioSciences, Inc. and Shanghai Junshi Biosciences Co., Ltd announced the publication of the final overall survival results from the pivotal JUPITER-02 study.
-
Coherus BioSciences Reports Third Quarter 2023 Financial Results and Business Highlights
11/6/2023
Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today reported financial results for the quarter ended September 30, 2023, and recent business highlights.
-
Coherus Presents Data from Next-generation Immuno-oncology Programs at 38th Annual Meeting of Society for Immunotherapy of Cancer (SITC)
11/3/2023
Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today announced data from three immuno-oncology pipeline programs at the 38th Annual Meeting of SITC taking place November 1 - 5, 2023 at the San Diego Convention Center in San Diego, CA.
-
Coherus BioSciences to Participate at Upcoming November 2023 Investor Conferences
11/3/2023
Coherus BioSciences, Inc. announced that senior management will participate in the following investor conferences.
-
Loqtorzi is the first programmed death receptor-1 from China to be approved by the U.S. regulator, and the first for patients with recurrent or metastatic nasopharyngeal carcinoma across all lines of treatment.
-
Coherus BioSciences to Report Third Quarter 2023 Financial Results on November 6, 2023
10/30/2023
Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) today announced that its third quarter 2023 financial results will be released after market close on Monday, November 6, 2023.
-
Coherus and Junshi Biosciences Announce FDA Approval of LOQTORZI™ (toripalimab-tpzi) in All Lines of Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
10/27/2023
Coherus BioSciences, Inc., and Shanghai Junshi Biosciences Co., Ltd. announced that the U.S. FDA approved LOQTORZI™ in combination with cisplatin and gemcitabine for the first-line treatment of adults with metastatic or recurrent locally advanced NPC, and as monotherapy for the treatment of adults with recurrent, unresectable, or metastatic NPC with disease progression on or after platinum-containing chemotherapy.
-
Coherus BioSciences Announces New Employment Inducement Grants - October 24, 2023
10/24/2023
Coherus BioSciences, Inc., announced that effective October 20, 2023, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 64,500 shares of the common stock of the Company to eight newly hired employees with a per share exercise price of $3.54, the closing trading price on the grant date.
-
Coherus Announces Toripalimab Data at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
10/14/2023
Coherus BioSciences, Inc., announced a presentation of toripalimab data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics being held October 11-15, 2023 at the Hynes Convention Center in Boston.
-
Coherus Announces Resubmission of Biologics License Application (BLA) Supplement for UDENYCA® ONBODY™
10/5/2023
Coherus BioSciences, Inc. (Coherus, NASDAQ: CHRS) today announced the Company has resubmitted the Biologics License Application (BLA) Supplement for UDENYCA® ONBODY™, the company's on-body injector presentation of UDENYCA® (pegfilgrastim-cbqv), to the U.S. Food and Drug Administration (FDA) for review.
-
CIMERLI® (ranibizumab-eqrn) Sales Exceed 100,000 Doses in First Year of Launch
10/4/2023
Coherus BioSciences, Inc., announced that sales of CIMERLI® to retinal specialists have exceeded 100,000 doses since commercial launch on October 3, 2022.
-
Coherus Applauds Congressional Designation of September 30th as Rare Cancer Day
10/2/2023
Coherus BioSciences, Inc. announced recognition and support for Rare Cancer Day to raise awareness for rare cancers such as nasopharyngeal carcinoma.
-
Coherus Announces Three Presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
9/27/2023
Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today announced the presentation of three abstracts from its innovative immuno-oncology pipeline at the upcoming SITC Annual Meeting taking place November 3 - 5, 2023 at the San Diego Convention Center in San Diego, CA.
-
FDA Issues Complete Response Letter (CRL) for UDENYCA® ONBODY™ Biologics License Application Solely Due to an Ongoing Review of Inspection Findings at a Third-Party Filler; Coherus Also Announces Completion of Toripalimab FDA Inspections
9/25/2023
Coherus BioSciences, Inc. announced that the U.S. Food and Drug Administration issued a Complete Response Letter regarding the Biologics License Application supplement for UDENYCA® ONBODY™, the company's on-body injector presentation of UDENYCA®, solely due to an ongoing review of inspection findings at a third-party filler.
-
Coherus BioSciences Announces New Employment Inducement Grants - September 23, 2023
9/23/2023
Coherus BioSciences, Inc., announced that effective September 20, 2023, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 109,000 shares of the common stock of the Company to six newly hired employees with a per share exercise price of $4.51, the closing trading price on the grant date.
-
Coherus Completes Surface Oncology Acquisition
9/8/2023
Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced the closing of the previously announced acquisition of Surface Oncology, Inc.
-
Coherus BioSciences to Participate at Upcoming September Investor Conferences
9/1/2023
Coherus BioSciences, Inc. (“Coherus“, Nasdaq: CHRS) today announced that senior management will participate in the following investor conferences.
-
Coherus BioSciences Announces New Employment Inducement Grants - August 22, 2023
8/22/2023
Coherus BioSciences, Inc., announced that effective August 20, 2023, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 77,000 shares of the common stock of the Company to newly hired employees with a per share exercise price of $4.47, the closing trading price on August 18, 2023, the last trading date preceding the grant date.
-
Coherus BioSciences Reports Second Quarter 2023 Financial Results and Business Highlights
8/2/2023
Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today reported financial results for the quarter ended June 30, 2023, and recent business highlights.